Logo image of NEO

NEOGENOMICS INC (NEO) Stock Fundamental Analysis

NASDAQ:NEO - Nasdaq - US64049M2098 - Common Stock - Currency: USD

11.1  -0.76 (-6.41%)

After market: 11.24 +0.14 (+1.26%)

Fundamental Rating

2

Overall NEO gets a fundamental rating of 2 out of 10. We evaluated NEO against 108 industry peers in the Health Care Providers & Services industry. NEO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NEO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NEO was profitable.
In the past year NEO had a positive cash flow from operations.
In the past 5 years NEO reported 4 times negative net income.
In the past 5 years NEO reported 4 times negative operating cash flow.
NEO Yearly Net Income VS EBIT VS OCF VS FCFNEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -4.74%, NEO is not doing good in the industry: 62.62% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -8.56%, NEO is in line with its industry, outperforming 44.86% of the companies in the same industry.
Industry RankSector Rank
ROA -4.74%
ROE -8.56%
ROIC N/A
ROA(3y)-4.66%
ROA(5y)-2.48%
ROE(3y)-8.18%
ROE(5y)-4.47%
ROIC(3y)N/A
ROIC(5y)N/A
NEO Yearly ROA, ROE, ROICNEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5 -10 -15

1.3 Margins

NEO has a Gross Margin of 43.54%. This is in the better half of the industry: NEO outperforms 69.16% of its industry peers.
NEO's Gross Margin has declined in the last couple of years.
NEO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-2.11%
NEO Yearly Profit, Operating, Gross MarginsNEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

3

2. Health

2.1 Basic Checks

NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for NEO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NEO Yearly Shares OutstandingNEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
NEO Yearly Total Debt VS Total AssetsNEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that NEO is in the distress zone and has some risk of bankruptcy.
NEO has a worse Altman-Z score (1.34) than 63.55% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that NEO is not too dependend on debt financing.
NEO has a better Debt to Equity ratio (0.37) than 60.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACC7.25%
NEO Yearly LT Debt VS Equity VS FCFNEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

NEO has a Current Ratio of 1.99. This is a normal value and indicates that NEO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.99, NEO is in the better half of the industry, outperforming 71.03% of the companies in the same industry.
A Quick Ratio of 1.91 indicates that NEO should not have too much problems paying its short term obligations.
NEO has a better Quick ratio (1.91) than 71.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.91
NEO Yearly Current Assets VS Current LiabilitesNEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 190.91% over the past year.
The earnings per share for NEO have been decreasing by -20.25% on average. This is quite bad
EPS 1Y (TTM)190.91%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.57%

3.2 Future

The Earnings Per Share is expected to grow by 84.99% on average over the next years. This is a very strong growth
Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 10.38% on average per year.
EPS Next Y90.15%
EPS Next 2Y91.83%
EPS Next 3Y84.99%
EPS Next 5YN/A
Revenue Next Year10.74%
Revenue Next 2Y10.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NEO Yearly Revenue VS EstimatesNEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
NEO Yearly EPS VS EstimatesNEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 111.00, which means the current valuation is very expensive for NEO.
NEO's Price/Earnings ratio is in line with the industry average.
NEO is valuated expensively when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
NEO is valuated quite expensively with a Price/Forward Earnings ratio of 58.37.
NEO's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, NEO is valued quite expensively.
Industry RankSector Rank
PE 111
Fwd PE 58.37
NEO Price Earnings VS Forward Price EarningsNEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEO Per share dataNEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NEO's earnings are expected to grow with 84.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.23
PEG (5Y)N/A
EPS Next 2Y91.83%
EPS Next 3Y84.99%

More info and screens

0

5. Dividend

5.1 Amount

NEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEOGENOMICS INC

NASDAQ:NEO (2/21/2025, 8:00:01 PM)

After market: 11.24 +0.14 (+1.26%)

11.1

-0.76 (-6.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-18 2025-02-18/bmo
Earnings (Next)04-28 2025-04-28/amc
Inst Owners98.16%
Inst Owner Change-85.64%
Ins Owners1.14%
Ins Owner Change-0.2%
Market Cap1.42B
Analysts80
Price Target20.49 (84.59%)
Short Float %2.97%
Short Ratio4.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)584.89%
Min EPS beat(2)298.27%
Max EPS beat(2)871.51%
EPS beat(4)4
Avg EPS beat(4)362.16%
Min EPS beat(4)59.66%
Max EPS beat(4)871.51%
EPS beat(8)8
Avg EPS beat(8)213.76%
EPS beat(12)12
Avg EPS beat(12)149.42%
EPS beat(16)15
Avg EPS beat(16)96.42%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.51%
Max Revenue beat(2)0.63%
Revenue beat(4)3
Avg Revenue beat(4)1.07%
Min Revenue beat(4)-0.51%
Max Revenue beat(4)3.2%
Revenue beat(8)7
Avg Revenue beat(8)3.69%
Revenue beat(12)9
Avg Revenue beat(12)2.77%
Revenue beat(16)12
Avg Revenue beat(16)2.1%
PT rev (1m)-2.94%
PT rev (3m)-2.03%
EPS NQ rev (1m)8.07%
EPS NQ rev (3m)8.07%
EPS NY rev (1m)0.54%
EPS NY rev (3m)17.9%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE 111
Fwd PE 58.37
P/S 2.21
P/FCF N/A
P/OCF 94.92
P/B 1.57
P/tB 38.09
EV/EBITDA N/A
EPS(TTM)0.1
EY0.9%
EPS(NY)0.19
Fwd EY1.71%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)0.12
OCFY1.05%
SpS5.02
BVpS7.08
TBVpS0.29
PEG (NY)1.23
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.74%
ROE -8.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.54%
FCFM N/A
ROA(3y)-4.66%
ROA(5y)-2.48%
ROE(3y)-8.18%
ROE(5y)-4.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-2.11%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.21%
Cap/Sales 5.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.91
Altman-Z 1.34
F-Score6
WACC7.25%
ROIC/WACCN/A
Cap/Depr(3y)68.11%
Cap/Depr(5y)70.39%
Cap/Sales(3y)8.05%
Cap/Sales(5y)7.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190.91%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%33.33%
EPS Next Y90.15%
EPS Next 2Y91.83%
EPS Next 3Y84.99%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.57%
Revenue Next Year10.74%
Revenue Next 2Y10.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year139.79%
EBIT Next 3Y41.77%
EBIT Next 5YN/A
FCF growth 1Y82.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.29%
OCF growth 3YN/A
OCF growth 5YN/A